Rakovina Therapeutics Inc. (RKV.V)
| Previous Close | 0.1850 |
| Open | 0.1850 |
| Bid | 0.2000 x N/A |
| Ask | 0.2150 x N/A |
| Day's Range | 0.1850 - 0.2500 |
| 52 Week Range | 0.1150 - 0.3000 |
| Volume | |
| Avg. Volume | 8,330 |
| Market Cap | 15.013M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0430 |
| Earnings Date | Nov 21, 2022 - Nov 25, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Rakovina Therapeutics Inc. Announces Q2 2022 Financial Results and Provides Corporate Update
VANCOUVER, British Columbia, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for the quarter ended June 30, 2022 and provided a corporate update. “We are pleased with the continued progress during this past quarter”, said Mr. Jeffrey Bacha executive chairman of Rakovina Therapeutics, Inc. “Our lead optimiz
- GlobeNewswire
Rakovina Therapeutics Announces Results from Annual General Meeting
VANCOUVER, British Columbia, June 23, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, is pleased to announce the results of voting at its 2022 Annual General Meeting of Shareholders held on June 23, 2022 (the “Meeting”). All four members of the Company’s Board of Directors named as nominees in its management information circular (the “Circular”
- Newsfile
Rakovina Therapeutics: Transform & Extend the Lives of Patients with Cancer, CEO Clip Video
Vancouver, British Columbia--(Newsfile Corp. - May 27, 2022) - Rakovina Therapeutics Inc. (TSXV: RKV) - The biotechnology company is developing precision medicines that selectively target and kill cancer cells using leading-edge science to discover and advance innovative cancer treatments with the potential to improve patient outcomes across multiple tumor types.If you cannot view the video above, please visit:https://b-tv.com/rakovina-therapeutics-transform-extend-the-lives-of-patients-with-can
